Drug Trial Radar · NCT03852433
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
May 31, 2019
Primary completion
Apr 5, 2022
Study completion Sep 28, 2022
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Feb 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
Conditions
- Chronic Hepatitis Delta
Interventions
BulevirtideDrug
Administered via subcutaneous injections
Peginterferon Alfa-2a (PEG-IFN alfa)Drug
Administered via subcutaneous injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24)Time frame: 24 weeks after EOT (Week 72 for Arm A and study Week 120 for Arms B, C, and D)
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital Beaujon-Pavillon Abrami -Sce Hépatologie
Clichy, France
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, France
Hospital Croix Rousee
Lyon, France
Hôpital Saint Joseph Hépato-Gastroentérologie
Marseille, France
CH Pitié-Salpétrière - Hépato-Gastroentérologie
Paris, France
Hôpital Cochin - Unité d'Hépatologie Pavillon Achard
Paris, France
Infectious Clinical Hospital "T. Ciorba", Department 4 / Medical University Department of Infectious Diseases
Chisinau, Moldova
Infectious Clinical Hospital "T. Ciorba", Department 5 / Medical University Department of Infectious Diseases
Chisinau, Moldova
"Matei Bals" National Institute of Infectious Diseases, Hospital department
Bucharest, Romania
"Matei Bals" National Institute of Infectious Diseases,Clinical Trials department
Bucharest, Romania
"Victor Babes" Centre of Diagnostic and Treatment
Bucharest, Romania
Dr. V. Babes Clinical Hospital of Infectious and Tropical Diseases
Bucharest, Romania
State Budgetary Educational Institution of Higher Professional Education "South Ural State Medical University" of the Ministry of Healthcare of the Russian Federation
Chelyabinsk, Russia
Specialized clinical Infectious diseases Hospital
Krasnodar, Russia
Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance
Moscow, Russia
Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation
Moscow, Russia
LLC"Clinic of Modern Medicine"
Moscow, Russia
Moscow Regional Scientific and Research Clinical Institute
Moscow, Russia
N.V.Sklifosovsky Scientific Research Institute of Emergency care of the Moscow Healthcare Department
Moscow, Russia
LLC Medical Company "Hepatolog"
Samara, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.